KTTA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pasithea Therapeutics Corp (KTTA) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock lacks significant positive catalysts, has weak financial performance, and no immediate trading signals. While the analyst rating is positive with a $3 price target, the company's current fundamentals and technical indicators do not support a compelling entry point.
The MACD is slightly positive but contracting, RSI is neutral at 42.809, and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level of 0.82, with support at 0.77 and resistance at 0.87.
Analyst Sara Nik from H.C. Wainwright initiated coverage with a Buy rating and a $3 price target, citing the company's next-generation MEK inhibitor targeting a $20B market opportunity.
and a significant EPS drop (-85.71% YoY). No significant insider or hedge fund trading activity.
In Q3 2025, revenue remained at $0 with no growth, net income was negative (-$3,037,420), and EPS dropped significantly (-85.71% YoY). Gross margin was also at 0%.
H.C. Wainwright initiated a Buy rating with a $3 price target, citing strong potential in the oncology and orphan drug markets.
